Skip to main content

In Rebranding Effort, Genstruct Changes Name to Selventa, Emphasizes Focus on Partnerships


Genstruct said this week that it has changed its name to Selventa as part of "an entire corporate rebranding effort" intended to emphasize its role as a data-analysis partner for drug developers and other clients.

The privately held company was founded in 2002 under the name Genstruct with a focus on using systems biology approaches to help customers discover biomarkers for personalized medicine.

In addition to the name change, Selventa this week reiterated its plans to focus on providing consulting services and software products, and to work with clients to select patient-specific treatments.

Diane Song, Selventa's marketing and scientific development manager, told BioInform via e-mail that the company is extending its consulting services by "offering software analytics and strategic partnering" with its clients, which she described as a "more focused business model" than the company had previously.

Specifically, the company said it plans to "embrace a customer-focused approach" that relies on existing patient data and "innovative analytics" to help drug developers "clarify decisions on therapeutics and diagnostics."

David de Graaf, chief scientific officer, said in a statement that the company's "new business strategy enables us to partner with clients at a deeper level to help them solve project portfolio development challenges and make a bigger impact on drug discovery."

He added that the new name, which comes from the Finnish selventää, which means "to clarify," reflects the company's "new focused approach."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.